SCHEMBL5122902

SCHEMBL5122902

CC(=O)Oc1ccc(C(=O)N2CCC(O)(C#Cc3cccc(Cl)c3)CC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.47
GRM5 P41594 5/20 0.45
GRM3 Q14832 1/20 0.45
KMT2A Q03164 2/20 0.45
POLB P06746 2/20 0.44
HPGD P15428 1/20 0.44
SMN1; SMN2 Q16637 1/20 0.44
ALDH1A1 P00352 3/20 0.44
MAPK1 P28482 2/20 0.44
TDP1 Q9NUW8 1/20 0.44
LMNA P02545 2/20 0.44
HTT P42858 1/20 0.44
ENPP2 Q13822 1/20 0.43
ATXN2 Q99700 1/20 0.43
MEN1 O00255 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
PKLR P30613 1/20 0.42
USP2 O75604 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP3A4 P08684 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5130117 0.88 GRM5 (0.44) MAPTGRM5KMT2APOLBHPGD
SCHEMBL5120360 0.88 HPGD (0.48) MAPTGRM5KMT2APOLBHPGD
SCHEMBL5129000 0.85 GRM5 (0.52) MAPTGRM5GRM3KMT2AHPGD
SCHEMBL5115603 0.85 MGLL (0.51) MAPTGRM5KMT2APOLBHPGD
SCHEMBL5130061 0.84 HSD11B1 (0.53) MAPTGRM5KMT2APOLBHPGD
SCHEMBL5129768 0.84 GRM5 (0.54) GRM5ALDH1A1ENPP2ATXN2MGLL
SCHEMBL5122942 0.83 PKLR (0.49) MAPTGRM5KMT2APOLBHPGD
SCHEMBL5115539 0.83 SMN1; SMN2 (0.50) MAPTGRM5KMT2APOLBHPGD
SCHEMBL5125577 0.83 PKM (0.47) GRM5KMT2AHPGDSMN1; SMN2ALDH1A1
SCHEMBL5129080 0.82 MGLL (0.53) MAPTGRM5KMT2APOLBHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists NOVARTIS AG (CH) 2008-10-30 US disclosed
EP-1856107-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS Novartis AG (CH) 2007-11-21 EP disclosed
WO-2006089700-A1 PYRROLIDINE AND PIPERIDINE ACETYLENE DERIVATIVES FOR USE AS MGLUR5 ANTAGONISTS NOVARTIS AG (CH) 2006-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080269250-A1 Pyrrolidine and Piperidine Acetylene Derivatives for Use as Mglur5 Antagonists GRM5, GRIK5, GRM1 MAPT 1486/4885GRM5 1/4885GRM3 13/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.